ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

Press

164 Posts
  • 비즈니스 와치

    [인사이드 스토리]신약개발 AI스타트업의 허와 실

    02-03-2020
  • 연합

    제일약품·온코크로스, 뇌졸중 신약 신규 용도 개발 계약

    01-15-2020
  • 조선비즈

    제일약품·온코크로스, AI 활용해 뇌졸중치료제 개발 계약 체결

    01-15-2020
  • 바이오스펙테이터

    제일약품-온코크로스 "AI로 신약물질 신규적응증 개발"

    01-15-2020
  • Korea Biomedical Review

    Jeil, Oncocross to discover new indications for stroke therapy

    01-15-2020
  • China BioMed

    中国医药创新与投资大会

    09-23-2019
  • 서울경제

    ‘AI+신약개발’에 뭉칫돈 몰린다…온코크로스, 60억 투자 유치

    07-29-2019
  • 월간파워코리아

    난치암 개선할 희망, 클라우딘 항체 기술 보유한 전문 벤처기업

    09-19-2016
  • «
  • ‹
  • 11
  • 12
  • 13
  • 14

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.